Clinically Negative phase III trials with Antiangiogenics (and their targets) in NSCL cancers:
1.Thalidomid -----an Antiangiogenic drug
2.Cediranib---------VEGFR TKI
3.Vandetanib--------Multikinase TKI
4.Sorafenib---------Multikinase TKI
5.Sunitinib----------Multikinase TKI
6.Aflibercept------------VEGF/PIGF
(from C.Langer notes)
No comments:
Post a Comment